Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma.

PURPOSE: This randomized phase III trial is comparing two combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III multiple myeloma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West of Scotland Lymphoma Group
• Treatments: Dexamethasone; Doxorubicin; Idarubicin; Liposomal doxorubicin; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of stage II or III multiple myeloma

• No prior therapy except local radiotherapy to bone lesions

• No indolent multiple myeloma

• No monoclonal gammopathy of unknown significance

PATIENT CHARACTERISTICS:

Age:

• 75 and under

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin no greater than 2.34 mg/dL

Renal:

• No end stage renal failure (creatinine greater than 5.65 mg/dL after rehydration)

• No requirement for dialysis

Other:

• No other medical condition that would preclude intensive treatment

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No other prior malignancy

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

Chemotherapy

• See Disease Characteristics

Endocrine therapy

• See Disease Characteristics

Radiotherapy

• Concurrent local radiotherapy allowed for painful lesions or lesions that appear likely to lead to an imminent fracture

Surgery

• See Disease Characteristics